Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Screen of existing drugs finds compounds active against MERS coronavirus


Research by NIH scientists, grantees identifies leads for further study

Clinicians treating patients suffering from Middle East respiratory syndrome (MERS) currently have no drugs specifically targeted to the MERS coronavirus (MERS-CoV), a virus first detected in humans in 2012 that has since caused 614 laboratory-confirmed infections, including 181 that were fatal, according to the World Health Organization.

The case count escalated sharply in the spring of this year, and the first cases in the United States were announced in early May. To address the urgent need for therapies, researchers supported by the National Institutes of Health screened a set of 290 compounds already approved by the U.S. Food and Drug Administration or far advanced in clinical development for other indications to determine if any might also show potential for working against MERS-CoV.

From the group of 290 compounds, the scientists identified 27 that, in test tube experiments, showed activity against both MERS-CoV and the related SARS coronavirus. These included compounds that inhibited the viruses' ability to enter and infect cells.

The active compounds belong to 13 different classes of pharmaceuticals, including drugs normally used to treat cancer and psychiatric conditions, and provide leads for continued study in animals and potentially for study in people. The research team is now studying the effects of some of the identified compounds in mice experimentally infected with MERS-CoV.

"Given development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses," the investigators noted in the paper now online in the journal Antimicrobial Agents and Chemotherapy. The research was a collaboration between investigators at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, and Matthew B. Frieman, Ph.D., of the University of Maryland School of Medicine in Baltimore.



J Dyall et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrobial Agents and Chemotherapy DOI: 10.1128/AAC.03036-14 (2014).


NIAID Director Anthony S. Fauci., M.D., is available to comment on this research. Co-author Lisa Hensley, Ph.D., associate director for science, NIAID Integrated Research Facility, is also available to discuss the findings.


To schedule interviews, please contact Anne A. Oplinger, (301) 402-1663,

For additional information about research on MERS and other coronaviruses by NIAID scientists and grantees, see:

The study was funded, in part, by NIAID grant AI095569.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH...Turning Discovery Into Health®

Anne A. Oplinger | Eurek Alert!

Further reports about: Allergy Infectious MERS MERS-CoV NIAID NIH Screen coronavirus diseases drugs investigators viruses

More articles from Studies and Analyses:

nachricht New Formula for Life-Satisfaction
01.10.2015 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Carbon storage in soils: Climate vs. Geology
14.09.2015 | Universität Augsburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Secure data transfer thanks to a single photon

Physicists of TU Berlin and mathematicians of MATHEON are so successful that even the prestigious journal “Nature Communications” reported on their project.

Security in data transfer is an important issue, and not only since the NSA scandal. Sometimes, however, the need for speed conflicts to a certain degree with...

Im Focus: A Light Touch May Help Animals and Robots Move on Sand and Snow

Having a light touch can make a hefty difference in how well animals and robots move across challenging granular surfaces such as snow, sand and leaf litter. Research reported October 9 in the journal Bioinspiration & Biomimetics shows how the design of appendages – whether legs or wheels – affects the ability of both robots and animals to cross weak and flowing surfaces.

Using an air fluidized bed trackway filled with poppy seeds or glass spheres, researchers at the Georgia Institute of Technology systematically varied the...

Im Focus: Reliable in-line inspections of high-strength automotive body parts within seconds

Nondestructive material testing (NDT) is a fast and effective way to analyze the quality of a product during the manufacturing process. Because defective materials can lead to malfunctioning finished products, NDT is an essential quality assurance measure, especially in the manufacture of safety-critical components such as automotive B-pillars. NDT examines the quality without damaging the component or modifying the surface of the material. At this year's Blechexpo trade fair in Stuttgart, Fraunhofer IZFP will have an exhibit that demonstrates the nondestructive testing of high-strength automotive body parts using 3MA. The measurement results are available in a matter of seconds.

To minimize vehicle weight and fuel consumption while providing the highest level of crash safety, automotive bodies are reinforced with elements made from...

Im Focus: Kick-off for a new era of precision astronomy

The MICADO camera, a first light instrument for the European Extremely Large Telescope (E-ELT), has entered a new phase in the project: by agreeing to a Memorandum of Understanding, the partners in Germany, France, the Netherlands, Austria, and Italy, have all confirmed their participation. Following this milestone, the project's transition into its preliminary design phase was approved at a kick-off meeting held in Vienna. Two weeks earlier, on September 18, the consortium and the European Southern Observatory (ESO), which is building the telescope, have signed the corresponding collaboration agreement.

As the first dedicated camera for the E-ELT, MICADO will equip the giant telescope with a capability for diffraction-limited imaging at near-infrared...

Im Focus: Locusts at the wheel: University of Graz investigates collision detector inspired by insect eyes

Self-driving cars will be on our streets in the foreseeable future. In Graz, research is currently dedicated to an innovative driver assistance system that takes over control if there is a danger of collision. It was nature that inspired Dr Manfred Hartbauer from the Institute of Zoology at the University of Graz: in dangerous traffic situations, migratory locusts react around ten times faster than humans. Working together with an interdisciplinary team, Hartbauer is investigating an affordable collision detector that is equipped with artificial locust eyes and can recognise potential crashes in time, during both day and night.

Inspired by insects

All Focus news of the innovation-report >>>



Event News

EHFG 2015: Securing healthcare and sustainably strengthening healthcare systems

01.10.2015 | Event News

Conference in Brussels: Tracking and Tracing the Smallest Marine Life Forms

30.09.2015 | Event News

World Alzheimer`s Day – Professor Willnow: Clearer Insights into the Development of the Disease

17.09.2015 | Event News

Latest News

Listening to the Extragalactic Radio

13.10.2015 | Physics and Astronomy

Penn study stops vision loss in late-stage canine X-linked retinitis pigmentosa

13.10.2015 | Health and Medicine

MRCE orders Vectron Locomotives

13.10.2015 | Press release

More VideoLinks >>>